Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 110.2% in January

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 743,709 shares, an increase of 110.2% from the December 31st total of 353,885 shares. Based on an average trading volume of 503,618 shares, the short-interest ratio is presently 1.5 days. Currently, 4.1% of the company’s shares are short sold. Currently, 4.1% of the company’s shares are short sold. Based on an average trading volume of 503,618 shares, the short-interest ratio is presently 1.5 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, October 9th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. HC Wainwright upgraded Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a report on Monday, October 13th. Royal Bank Of Canada cut their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, November 4th. Finally, Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $6.52 on Friday. The firm has a market cap of $119.38 million, a price-to-earnings ratio of -0.45 and a beta of 0.21. The firm has a 50 day simple moving average of $6.72 and a 200-day simple moving average of $6.06. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.38.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The business had revenue of $44.04 million for the quarter, compared to the consensus estimate of $39.56 million. Equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ADAR1 Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the 3rd quarter valued at about $164,000. Bridgeway Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth about $163,000. Bank of America Corp DE increased its stake in shares of Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $56,000. Finally, Baird Financial Group Inc. purchased a new position in Karyopharm Therapeutics in the second quarter worth approximately $45,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.